Targeted Immune Cell Activation by Systemic Delivery of Toll-Like Receptor 9 Agonist Antibody Conjugates Induces Potent Anti- Tumor Immunity

Time: 3:00 pm
day: Day One


  • Identify how activation of toll-like receptor 9 (TLR9) by unmethylated CpG oligonucleotides promotes innate inflammatory responses and induction of adaptive immunity
  • Review our novel Toll-Like Receptor Agonist Antibody Conjugate (TRAAC) platform developed to deliver a potent TLR9 (T-CpG agonist for targeted immune activation via systemic administration
  • Evaluate various TRAAC approaches targeting either immune cell receptor or tumor specific antigens in preclinical settings